SG10201912565QA - Low-viscosity antigen binding proteins and methods of making them - Google Patents
Low-viscosity antigen binding proteins and methods of making themInfo
- Publication number
- SG10201912565QA SG10201912565QA SG10201912565QA SG10201912565QA SG10201912565QA SG 10201912565Q A SG10201912565Q A SG 10201912565QA SG 10201912565Q A SG10201912565Q A SG 10201912565QA SG 10201912565Q A SG10201912565Q A SG 10201912565QA SG 10201912565Q A SG10201912565Q A SG 10201912565QA
- Authority
- SG
- Singapore
- Prior art keywords
- viscosity
- making
- methods
- low
- antigen binding
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
- G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
- G01N11/14—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401770P | 2016-09-29 | 2016-09-29 | |
| US201662430773P | 2016-12-06 | 2016-12-06 | |
| US201762546469P | 2017-08-16 | 2017-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912565QA true SG10201912565QA (en) | 2020-02-27 |
Family
ID=60245172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912565QA SG10201912565QA (en) | 2016-09-29 | 2017-09-28 | Low-viscosity antigen binding proteins and methods of making them |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11059908B2 (en) |
| EP (1) | EP3519439A2 (en) |
| JP (3) | JP2019532063A (en) |
| KR (2) | KR102551269B1 (en) |
| CN (1) | CN110036031A (en) |
| AU (1) | AU2017336673A1 (en) |
| CA (1) | CA3038909A1 (en) |
| CL (2) | CL2019000835A1 (en) |
| IL (2) | IL307684A (en) |
| MA (1) | MA46359A (en) |
| MX (1) | MX2019003727A (en) |
| SG (1) | SG10201912565QA (en) |
| WO (1) | WO2018064307A2 (en) |
| ZA (1) | ZA201902297B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013004841A1 (en) * | 2011-07-06 | 2013-01-10 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
| PT2953634T (en) | 2013-02-07 | 2021-09-02 | Massachusetts Gen Hospital | Methods for expansion or depletion of t-regulatory cells |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| US11813328B2 (en) | 2014-10-23 | 2023-11-14 | Amgen Inc. | Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins |
| CN116715767A (en) | 2016-05-13 | 2023-09-08 | 综合医院公司 | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| JP7377596B2 (en) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | Low viscosity, high concentration evolocumab formulations and their manufacturing method |
| KR20190132215A (en) | 2018-05-18 | 2019-11-27 | 서울반도체 주식회사 | Light emitting diode, light emitting diode module and display device having the same |
| WO2020041361A1 (en) * | 2018-08-20 | 2020-02-27 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| WO2020185763A1 (en) * | 2019-03-11 | 2020-09-17 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| CN114729056A (en) * | 2019-06-26 | 2022-07-08 | 阿穆尼克斯制药公司 | EGFR antigen binding fragments and compositions comprising the same |
| WO2021202013A1 (en) * | 2020-03-30 | 2021-10-07 | Crystal Bioscience Inc. | Anti-gipr antibody and methods of use thereof |
| CN113512116B (en) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | anti-IGF-1R antibody and application thereof |
| WO2022011264A2 (en) * | 2020-07-10 | 2022-01-13 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against rotavirus |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
| AR083495A1 (en) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | STABLE AND SOLUBLE ANTIBODIES |
| WO2012125495A2 (en) | 2011-03-11 | 2012-09-20 | Amgen Inc. | Method of correlated mutational analysis to improve therapeutic antibodies |
| JOP20200043A1 (en) * | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
| HRP20211641T1 (en) * | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| RU2019108429A (en) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION |
| EP3026061A1 (en) * | 2014-11-26 | 2016-06-01 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
| SG11201805255TA (en) * | 2015-12-23 | 2018-07-30 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
-
2017
- 2017-09-28 CA CA3038909A patent/CA3038909A1/en active Pending
- 2017-09-28 AU AU2017336673A patent/AU2017336673A1/en active Pending
- 2017-09-28 EP EP17794111.9A patent/EP3519439A2/en active Pending
- 2017-09-28 SG SG10201912565QA patent/SG10201912565QA/en unknown
- 2017-09-28 KR KR1020197012239A patent/KR102551269B1/en active IP Right Grant
- 2017-09-28 JP JP2019516945A patent/JP2019532063A/en active Pending
- 2017-09-28 KR KR1020237022133A patent/KR20230107696A/en not_active Application Discontinuation
- 2017-09-28 WO PCT/US2017/053967 patent/WO2018064307A2/en active Application Filing
- 2017-09-28 IL IL307684A patent/IL307684A/en unknown
- 2017-09-28 CN CN201780073880.7A patent/CN110036031A/en active Pending
- 2017-09-28 IL IL265692A patent/IL265692B2/en unknown
- 2017-09-28 US US16/338,292 patent/US11059908B2/en active Active
- 2017-09-28 MA MA046359A patent/MA46359A/en unknown
- 2017-09-28 MX MX2019003727A patent/MX2019003727A/en unknown
-
2019
- 2019-03-28 CL CL2019000835A patent/CL2019000835A1/en unknown
- 2019-04-11 ZA ZA2019/02297A patent/ZA201902297B/en unknown
-
2021
- 2021-06-11 US US17/346,156 patent/US20210371544A1/en active Pending
- 2021-12-31 CL CL2021003596A patent/CL2021003596A1/en unknown
-
2022
- 2022-03-18 JP JP2022043944A patent/JP2022081654A/en active Pending
-
2023
- 2023-10-24 JP JP2023182462A patent/JP2023178409A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110036031A (en) | 2019-07-19 |
| US11059908B2 (en) | 2021-07-13 |
| IL307684A (en) | 2023-12-01 |
| JP2022081654A (en) | 2022-05-31 |
| US20190233543A1 (en) | 2019-08-01 |
| WO2018064307A3 (en) | 2018-07-05 |
| IL265692A (en) | 2019-05-30 |
| KR102551269B1 (en) | 2023-07-05 |
| WO2018064307A2 (en) | 2018-04-05 |
| KR20190053271A (en) | 2019-05-17 |
| ZA201902297B (en) | 2019-12-18 |
| CA3038909A1 (en) | 2018-04-05 |
| JP2023178409A (en) | 2023-12-14 |
| AU2017336673A1 (en) | 2019-04-18 |
| JP2019532063A (en) | 2019-11-07 |
| MA46359A (en) | 2019-08-07 |
| CL2021003596A1 (en) | 2022-08-19 |
| WO2018064307A4 (en) | 2018-09-27 |
| MX2019003727A (en) | 2019-08-05 |
| CL2019000835A1 (en) | 2019-05-31 |
| IL265692B2 (en) | 2024-03-01 |
| KR20230107696A (en) | 2023-07-17 |
| IL265692B1 (en) | 2023-11-01 |
| EP3519439A2 (en) | 2019-08-07 |
| US20210371544A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201902297B (en) | Low-viscosity antigen binding proteins and methods of making them | |
| IL264211A (en) | Multispecific antigen binding proteins and methods of use thereof | |
| IL261666A (en) | Binding proteins and methods of use thereof | |
| IL281783A (en) | Sirpα binding proteins and methods of use thereof | |
| IL261432A (en) | Inducible binding proteins and methods of use | |
| IL275782A (en) | Multispecific antigen binding proteins and methods of use thereof | |
| ZA201808160B (en) | Bispecific binding proteins and uses thereof | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of use thereof | |
| HK1251158A1 (en) | Pd-1 binding proteins and methods of use thereof | |
| ZA201904491B (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| IL268658A (en) | Anti-tau antibodies and methods of use thereof | |
| IL246921B (en) | Binding proteins and methods of use thereof | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| EP3635013A4 (en) | Nectin-4 binding proteins and methods of use thereof | |
| ZA201903578B (en) | Anti-tau antibodies and methods of use | |
| IL281970B (en) | Methods of using bispecific cd33 and cd3 binding proteins | |
| IL266913A (en) | Anti-tau antibodies and methods of their use | |
| ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| IL279201A (en) | Multi-specific binding proteins and methods of use thereof | |
| IL265957A (en) | Anti-c1s antibodies and methods of use thereof | |
| PL3484488T3 (en) | Antigen binding molecules and methods of use thereof | |
| IL267565A (en) | Binding polypeptides and methods of making the same | |
| GB201614627D0 (en) | Antigen binding proteins |